Telesystem Launches Enhanced UCaaS Solution, TrustUC
TrustUC offers users a seamless communications experience on any device, integrating the Webex communication platform with new AI-driven functionalities that optimize employee engagement and productivity. Key features, including AI-Powered Meeting Summaries and customizable conversational AI Agents enable businesses to boost operational efficiencies and improve customer experiences.
"We are very excited to introduce TrustUC to the marketplace," said Bruce Wirt, Chief Revenue Officer at Telesystem. "Security and Customer experience are equally at the center of our value proposition, and we're excited to showcase the ease of use and feature rich capabilities in this state-of-the-art platform. TrustUC is Telesystem's answer to businesses who are frustrated by the multitude of applications to try and satisfy their need for end user security, voice, collaboration, and messaging in a simplistic format. By combining these solutions, users will find an easy-to-use solution that gives them all the tools needed to run their communications from a single source." Wirt continued.
With a focus on helping businesses improve their cybersecurity posture, Telesystem has embedded their employee Security Awareness Training solution directly into the TrustUC platform, empowering organizations to educate their employees on current cyber threats such as SPAM, phishing, malware, ransomware, and social engineering. Additionally, the integration gives businesses access to 24/7 dark web monitoring, micro-trainings and unlimited phishing simulations.
In addition to advanced collaboration and security tools, all TrustUC seats are integrated with the free tier of Telesystem's new Business Messaging solution, enabling businesses to communicate securely and efficiently across multiple channels, including SMS, MMS, and iMessage within the TrustUC application.
Telesystem's TrustUC Business Messaging solution offers a number of key features, including bulk messaging for promotions or announcements, and automated responses for common inquiries, appointment reminders and confirmations. Additionally, its embedded AI capabilities can automatically analyze messaging patterns and customer responses; helping refine and automate communication strategies, predict customer needs, and provide smarter, context-aware replies that will significantly improve engagement and customer satisfaction.
Integrating Security Awareness Training and Business Messaging into Webex's AI functionality makes TrustUC a powerful tool for businesses in one central application. Users can access the app from any device, giving them the freedom to work how and where they want, while enjoying a more secure, engaging, and fully integrated communication experience. For more information about TrustUC and its pricing and features, please visit: www.TrustTelesystem.com/TrustUC.
About Telesystem
For over 30 years, Telesystem has been a trusted technology partner for SME and mid-market US-based organizations, empowering businesses across the country with a range of innovative cybersecurity, networking and communication solutions designed to address the business-specific needs of each customer. Guided by strategic partnerships and a customer-centric mission, these customized solutions are backed by an end-to-end managed experience and 24/7 US-based support team.
Telesystem provides service to businesses in all areas of the United States. Their customers include hospitals, universities, local public and private school districts, banks, multi-location retail establishments and regional government offices, just to name a few. To learn more about Telesystem vist www.TrustTelesystem.com
Contact Information
Morgan Hull Marketing Generalistmhull@telesystem.us
SOURCE: Telesystem
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
2 minutes ago
- Miami Herald
AI and Virtual Coaching Are Transforming Reemployment - Big Interview Shows What's Possible
NEW YORK CITY, NY / ACCESS Newswire / August 21, 2025 / As the White House releases its America's Talent Strategy: Building the Workforce for the Golden Age, state agencies are facing an urgent question: how to prepare workers for a job market being reshaped at unprecedented speed by AI and automation. The challenge is clear. By 2030, 14% of workers will need to change jobs due to AI and automation, and 80% of the workforce will see disruption to their daily tasks from large language models like ChatGPT (McKinsey). Reemployment programs, built for a pre-AI economy, are struggling to keep pace. The paradox is that the same technologies fueling disruption may also be the key to recovery. Across the country, workforce agencies are piloting AI-powered assessments, virtual reality training, and AI-driven interview coaching to move people back into work faster and with better job matches. "Over the last decade, I've watched hiring trends shift-but nothing compares to the pace of change we're seeing now," said Pamela Skillings, co-founder and chief coach at Big Interview. "AI isn't just changing what jobs exist, it's changing how quickly people need to adapt. Agencies that integrate these tools now will be the ones that keep their workers competitive." AI-enabled resume and interview tools-like those built into Big Interview-are helping states like Idaho provide personalized interview feedback to thousands of unemployed residents annually, without increasing staff workload. These same approaches are in line with the White House's America's Talent Strategy Pillar IV and V priorities: Accountability: Linking investments to clear employment outcomes, shortening unemployment, and redirecting resources to programs that prove & Innovation: Using AI-era tools to pilot new models, adapt training to labor market needs, and scale access to rural and underserved communities. For state agencies, the impact is measurable. Big Interview's AI-driven mock interview simulations and resume optimization tools have already supported over two million job seekers worldwide, helping them land jobs up to 5x faster than the national average. "When you can serve thousands of people with personalized interview feedback-without adding staff-you're not just innovating, you're solving real problems," said Steve Ruder, Vice President at Big Interview. "We've seen measurable results in multiple states, and the technology is proven to scale." As agencies evaluate their next steps under the America's Talent Strategy report, one priority stands out: evaluate and pilot AI-driven tools that can scale impact, measure results, and adapt quickly to changing labor market needs. Contact Information Steve Ruder Vice Presidentsteve@
Miami Herald
2 minutes ago
- Miami Herald
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Enrollment has reached approximately 25% in Jaguar's ongoing field study of Canalevia-CA1 in dogs SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is participating in the 2025 Animal Health Summit in support of the company's goal of securing a collaboration to expand the indication of Canalevia (crofelemer delayed-release tablets) from treatment of chemotherapy-induced diarrhea (CID) in dogs to treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) for treatment of CID in dogs. The Animal Health Summit, hosted by KC Animal Health Corridor, takes place August 25-26, 2025 in Kansas City, Missouri. "I'm pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of Canalevia for treatment of general diarrhea in dogs," said Lisa Conte, Jaguar's Founder and CEO. "Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs; obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs. Forging a partnership to support these goals is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for Jaguar this year." "Our goal is to be as comprehensive as possible in the search for the best partner for Canalevia - and with this goal in mind we look forward to participating in the 2025 Animal Health Summit. Our team is available for partnership discussions at the event," said David Sesin, PhD, Jaguar's Chief Manufacturing Officer. A report by the American Veterinary Medical Foundation concluded that there were approximately 90 million dogs in the U.S. in 2024, of which Jaguar estimates more than 11 million suffer from general diarrhea each year. Data from the European Pet Food Industry Federation concluded that there were approximately 104 million dogs in Europe in 2022. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the U.S. and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general diarrhea in dogs - both in the U.S. and the EU," said Conte. "We estimate that U.S. veterinarians see approximately four million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general diarrhea in the U.S. and/or globally." As announced, enrollment has begun in Jaguar's ongoing full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs. With multiple veterinary oncology clinics signed on to take part in this study, enrollment has reached 25%, and Jaguar is in discussions with other veterinary oncology clinics regarding possible participation. The objective of this ongoing, prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs - the fourth and final technical section required to support potential full FDA approval of the drug for dogs with CID. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected for the control group. Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics. "In the EU, as we announced, it may be possible to obtain approval of Canalevia for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea," Conte said. "While this completed trial did not meet its stated primary endpoint, the study results are clinically significant when analyzed using an alternate endpoint, defining treatment success as any dog that had no episodes of diarrhea following the first treatment with either Canalevia or placebo. Using this revised endpoint, the study data shows that dogs treated with Canalevia resolved their diarrhea within 24 hours of the first administration of the drug, with the data demonstrating statistical and clinical relevance compared to placebo-treated dogs." Jaguar plans to submit a dossier to the European Medicines Agency (EMA) to outline the results of the updated analysis of the company's completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application (MAA) for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs. Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy. About Conditional Approval and Full Approval Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA's conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the "substantial evidence" standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving "substantial evidence of effectiveness" for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug. About Chemotherapy-induced Diarrhea (CID) in Dogs According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.1 According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S. Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID. Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs. About Canalevia®-CA1 Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a "small number" threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use. About Crofelemer Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities. Important Safety Information About Canalevia®-CA1 For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that company personnel will attend the 2025 Animal Health Summit, Jaguar's expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in dogs with general diarrhea, Jaguar's expectation that it will submit a dossier to the EMA to outline the results of the updated analysis of the company's completed study of Canalevia in dogs with general diarrhea, Jaguar's expectation that, if the dossier is acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs to the EMA, and Jaguar's expectation that, if the application is approved by the EMA, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 1 "Cancer in Pets." American Veterinary Medical Association, 2021, 2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398 Source: Jaguar Health, Inc. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Yahoo
an hour ago
- Yahoo
Quoin Pharmaceuticals' NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome
ASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ('Quoin' or the 'Company'), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that its NETHERTON NOW awareness campaign has surpassed a major milestone, achieving more than one million video views and over 14 million impressions. Launched to give patients, families, and experts a greater voice, NETHERTON NOW has become a global platform shining a spotlight on the painful realities of Netherton Syndrome (NS), a rare and devastating genetic skin disease. The campaign's videos, which highlight personal stories and clinical perspectives, have been widely circulated on social media with placement on major outlets including MSN, Today, and CBS News, as well as in clinical publications such as ScienceDirect. 'Surpassing one million views and 14 million impressions is a milestone that reflects how far the NETHERTON NOW campaign has come,' said Denise Carter, Quoin's Co- Founder and Chief Operating Officer. 'What began as an idea to raise awareness has become a global platform that brings the harsh realities of living with Netherton Syndrome into the spotlight. We are honored to share the voices of international advocates, patients, families, and clinical experts. Together, these stories are changing how the world understands this devastating disease, building momentum within both the treatment community and the general public, and further reinforce our determination to deliver the first approved treatment.' Quoin's lead investigational candidate, QRX003, is currently being studied in late-stage clinical trials for the treatment of Netherton Syndrome. Both studies are designed to evaluate QRX003 as monotherapy and in combination with off-label systemic treatments. Recruitment is underway across multiple U.S. and international sites, with full enrollment expected in early to mid-Q1 2026. 'As we progress QRX003 through the last stages of clinical development, we remain laser-focused on the possibility of delivering the first approved treatment for Netherton Syndrome,' said Dr. Michael Myers, Co-Founder and Chief Executive Officer of Quoin Pharmaceuticals. 'Early data have shown encouraging signals, and these later studies have been designed to support obtaining the broadest possible label for the product. The voices shared in NETHERTON NOW serve as a powerful reminder of the urgent unmet need in this community and strengthen our commitment to advancing meaningful therapies.' The NETHERTON NOW campaign is an ongoing initiative from Quoin to raise awareness, improve education, and elevate the voices of patients, caregivers, and experts in the field. About Quoin Pharmaceuticals Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The company is committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma, and others. For more information, visit or follow Quoin on LinkedIn for updates. For more information about Netherton Syndrome, Quoin's clinical programs, or to stay updated on the NETHERTON NOW series, visit Cautionary Note Regarding Forward Looking StatementsThe Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as 'aim,' 'design,' 'expect,' 'hope,' 'intend,' 'plan,' 'anticipate,' 'believe,' and 'will,' among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: determination to deliver the first approved treatment for Netherton Syndrome; full enrollment in studies expected in early to mid-Q1 2026; possibility of delivering the first approved treatment for Netherton Syndrome; the potential of QRX003 as a treatment for Netherton Syndrome; and Quoin's products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company's ability to deliver a safe and effective treatment for Netherton Syndrome; whether the Company's studies are successful in generating data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton Syndrome; and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. For further information, contact: Quoin Pharmaceuticals Myers, Ph.D., CEOmmyers@ Investor RelationsPCG AdvisoryJeff Ramsonjramson@ (646) 863-6341Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
